In CTCL, tumor-secreted galectin-1 inhibits the viability, proliferation, and Th1 response of non-malignant T cells and promotes the Th2 response that is conducive to tumor survival (102). This evidence concerns the gene LGALS1 and primary cutaneous T-cell non-Hodgkin lymphoma.